UNRESECTABLE NUT CARCINOMA
Clinical trials for UNRESECTABLE NUT CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE NUT CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE NUT CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human trial tests new drug duo against aggressive cancers
Disease control Recruiting nowThis early-stage study aims to find the safest dose of two oral drugs—ZEN003694 and abemaciclib—when given together to patients with advanced cancers that have spread or cannot be removed by surgery. The trial will enroll about 45 adults and teens (12+) with specific cancers, inc…
Matched conditions: UNRESECTABLE NUT CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for rare, aggressive cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study is testing a new oral drug, ZEN003694, in combination with standard chemotherapy for people with advanced NUT carcinoma, a rare and aggressive cancer. The main goals are to find a safe dose of the combination and see if it helps shrink tumors or slow the cancer's growt…
Matched conditions: UNRESECTABLE NUT CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for rare, aggressive cancer: immunotherapy trial opens
Disease control Recruiting nowThis study is testing if the immunotherapy drug cemiplimab can help control advanced NUT carcinoma, a rare and aggressive cancer with very few treatment options. It will enroll about 15 adults whose cancer has spread or cannot be removed by surgery. The main goal is to see if the…
Matched conditions: UNRESECTABLE NUT CARCINOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC